ETF Evaluator:
Invesco Nasdaq Biotechnology ETF ()
Follow This ETF
(as of Aug 26)
Best Performing in Health Over the Last Year
| 129.4% | Virtus LifeSci Biotech Clinical Trls ETF (BBC) |
| 94.1% | ALPS Medical Breakthroughs ETF (SBIO) |
| 88.4% | F/m Emerald Life Sciences Innovation ETF (LFSC) |
| 72.5% | State Street® SPDR® S&P® Biotech ETF (XBI) |
| 65.8% | State Street® SPDR® S&P® PhrmctlsETF (XPH) |
Risk
Index
Risk
Index
ETF Details
Invesco Nasdaq Biotechnology ETF Overview
Invesco Nasdaq Biotechnology ETF (IBBQ) is a passively managed Sector Equity Health exchange-traded fund (ETF). Invesco launched the ETF in 2021.
The investment seeks to track the investment results (before fees and expenses) of the Nasdaq Biotechnology Index ®.
The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capitalization companies. The fund is non-diversified.
About Invesco Nasdaq Biotechnology ETF (IBBQ)
There are 3 members of the management team with an average tenure of 5.14 years: Peter Hubbard (2021), Michael Jeanette (2021) and Pratik Doshi (2021). Management tenure is more important for actively managed ETFs than passive index ETFs.
The ETF has 2 primary benchmarks: NASDAQ Composite TR USD index with a weighting of 100% and NASDAQ Biotechnology TR USD index with a weighting of 100%. Invesco Nasdaq Biotechnology ETF has 258 securities in its portfolio. The top 10 holdings constitute 42.3% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is not considered to have an ESG focus with its investment selection and management.
Invesco Nasdaq Biotechnology ETF is part of the Equity global asset class and is within the Sector Equity ETF group. Invesco Nasdaq Biotechnology ETF has 5.4% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 94.5% There is 5.4% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Invesco Nasdaq Biotechnology ETF has 0.1% of the portfolio in cash.
Assets Under Management
The fund has $76 million in total assets, which is below the $1 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
IBBQ Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Invesco Nasdaq Biotechnology ETF expense ratio is low compared to funds in the Health category. Invesco Nasdaq Biotechnology ETF has an expense ratio of 0.19%, which is 63% lower than its category average, making the fund expense ratio grade a A. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. Invesco Nasdaq Biotechnology ETF has a portfolio turnover rate of 17%, which indicates that it holds its assets around / 0.1 years. By way of comparison, the average portfolio turnover is 45% for the Health category.
Recently, in the month of July 2026, Invesco Nasdaq Biotechnology ETF returned -1.7%, which earned it a grade of D, as the Health category had an average return of -0.1%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
Invesco Nasdaq Biotechnology ETF has a trailing yield of 0.80%, which is below the 1.10% category average.
The fund normally distributes its income quarterly.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
Invesco Nasdaq Biotechnology ETF Grades
Year to date, the ETF has returned 13.3%, 3.6 percentage points better than the category, which translates into a grade of B. The fund has returned 45.4% over the past year (grade of B), 16.8% over the past three years (grade of A) and 5.4% per year over the past five years (grade of B).
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about Invesco Nasdaq Biotechnology ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
IBBQ Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| IBBQ Return (NAV) | -1.7% | 10.2% | 45.4% | 16.8% | 5.4% | na |
| IBBQ Return (Price) | -1.7% | 10.2% | 45.5% | 16.9% | 5.4% | na |
| NAV +/- Price Return | -0.004% | -0.033% | -0.156% | -0.044% | -0.030% | na |
| Health Avg | -0.1% | 11.2% | 36.9% | 9.9% | 1.6% | 8.7% |
| IBBQ Grade (NAV) | D | D | B | A | B | na |
| +/- Category (NAV) | -1.6% | -1.1% | 8.5% | 6.9% | 3.8% | na |
| IBBQ Tax-Cost Ratio | na | na | 0.4% | 0.3% | 0.3% | na |
IBBQ Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| IBBQ Return (NAV) | 13.3% | 33.4% | -0.6% | 4.5% | -10.2% | na | na | na | na | na | na |
| IBBQ Return (Price) | 13.3% | 33.3% | -0.6% | 4.7% | -10.4% | na | na | na | na | na | na |
| NAV +/- Price Ret | 0.001% | -0.001% | -0.004% | 0.054% | 0.016% | na | na | na | na | na | na |
| Health Avg | 9.7% | 21.8% | 0.1% | 2.2% | -16.3% | 4.3% | 30.5% | 25.4% | -1.5% | 26.5% | -10.2% |
| IBBQ Grade (NAV) | B | A | D | B | C | na | na | na | na | na | na |
| +/- Category | 3.6% | 11.6% | -0.7% | 2.3% | 6.1% | na | na | na | na | na | na |
| Risk Measures | |
| Beta: | 0.62 |
| R-Squared: | 22% |
| Standard Deviation: | 16.9% |
| Category Risk Index: | 0.84 |
| Category Risk Rating: | Average |
| Total Risk Index: | 1.38 |
| Total Risk Rating: | Above Average |
| Portfolio Characteristics | |
| Yield: | 0.8% |
| Total Assets: | $ 76 Mil |
| Share Class Assets: | $ 76 Mil |
| Turnover: | 17.0% |
| Expense Ratio: | 0.19% |
| Index Fund: | Yes |
| Index Tracked: | NASDAQ Composite TR USD |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | No |
| Capital Gains Distribution Frequency: | |
| Income Distribution Frequency: | Quarterly |
Management Team
| Number of Managers: 3 | |||
| Longest Tenure: 5.1 years | |||
| Average Tenure: 5.1 years | |||
| Managers (Year): Hubbard Peter (2021), Jeanette Michael (2021), Doshi Pratik (2021) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 258 |
| % in Top 10 Holdings: | 42.3% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 5.4% |
Portfolio Allocation |
|
| Domestic Stock: | 94.5% |
| Foreign Stock: | 5.4% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.1% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | Invesco |
| Phone Number: | 800-983-0903 |
| Website: | www.invescopowershares.com |
| Inception Date: | June 11, 2021 |
Expenses and Fees
| Expense Ratio (%): | 0.19% (Rating: Low) |
| Category Average Expense Ratio (%): | 0.52% |
